NCT01919164 arm group e52129f1342fd4c8dc2942de85f47adf [clinicaltrials_resource:NCT01919164/arm-group/e52129f1342fd4c8dc2942de85f47adf]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01919164 arm group e52129f1342fd4c8dc2942de85f47adf [clinicaltrials_resource:NCT01919164/arm-group/e52129f1342fd4c8dc2942de85f47adf]
Bio2RDF identifier
NCT01919164/arm-group/e52129f1342fd4c8dc2942de85f47adf
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 2129f1342fd4c8dc2942de85f47adf
description [clinicaltrials_vocabulary:description]
AS902330, 30 mcg, will be admi ...... ks, with follow-up to 2 years.
identifier
clinicaltrials_resource:NCT01919164/arm-group/e52129f1342fd4c8dc2942de85f47adf
title
NCT01919164 arm group e52129f1342fd4c8dc2942de85f47adf
@en
type
label
NCT01919164 arm group e52129f1 ...... 129f1342fd4c8dc2942de85f47adf]
@en